Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BCL9 | O00512 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | POLM | Q9NP87 | 1/20 | 0.39 |
| ▸ | POLK | Q9UBT6 | 1/20 | 0.39 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.39 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11456688 | 0.90 | KDM4E (0.61) | KDM4EMEN1RECQLKMT2AALOX15 | |
| SCHEMBL27754492 | 0.88 | KDM4E (0.53) | KDM4EMEN1RECQLKMT2AALOX15 | |
| SCHEMBL7620644 | 0.86 | ALOX15 (0.45) | KDM4EMEN1RECQLKMT2AALOX15 | |
| SCHEMBL2901718 | 0.84 | MEN1 (0.37) | KDM4EMEN1RECQLKMT2AALOX15 | |
| SCHEMBL9312497 | 0.84 | KMT2A (0.59) | KDM4EMEN1RECQLKMT2AALOX15 | |
| SCHEMBL27491120 | 0.83 | KDM4E (0.49) | KDM4EMEN1RECQLKMT2AALOX15 | |
| SCHEMBL3144843 | 0.83 | KDM4E (0.49) | KDM4EMEN1RECQLKMT2AALOX15 | |
| SCHEMBL30716629 | 0.82 | MEN1 (0.48) | KDM4EMEN1RECQLKMT2AALOX15 | |
| SCHEMBL27859637 | 0.82 | THRA (0.57) | KDM4EMEN1RECQLKMT2AALOX15 | |
| SCHEMBL15548869 | 0.81 | ALOX15 (0.53) | KDM4EMEN1RECQLKMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101531631-A | Substituted pyridinones as modulators of p38 map kinase | PHARMACIA CORP (US) | 2009-09-16 | — | — | CN | disclosed |
| CN-100486576-C | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2009-05-13 | — | — | CN | disclosed |
| CN-101296914-A | Derivatives with PPAR agonist activity | SHIONOGI & CO (JP) | 2008-10-29 | — | — | CN | disclosed |
| CN-1646125-A | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2005-07-27 | — | — | CN | disclosed |
| US-20050154007-A1 | New compounds | AMIN KOSRAT (SE) | 2005-07-14 | — | — | US | disclosed |
| US-6790960-B2 | Compounds | ASTRAZENECA AB (SE) | 2004-09-14 | — | — | US | disclosed |
| EP-1454898-A1 | NOVEL PHENYLALANINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2004-09-08 | — | — | EP | disclosed |
| EP-1411056-A2 | Imidazo[1,2-a]pyridine compounds that inhibit gastric acid secretion, pharmaceutical compositions thereof, and processes for their preparation | AstraZeneca AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| US-20030220364-A1 | New compounds | AMIN KOSRAT (SE) | 2003-11-27 | — | — | US | disclosed |
| US-6579884-B1 | Compounds | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| EP-1105391-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000011000-A2 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-02 | — | — | WO | disclosed |
| EP-0773931-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996002506-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220364-A1 | New compounds | SLC10A2, GIPR, FABP2 | KDM4E 4741/4885MEN1 3250/4885RECQL 3374/4885 |
| US-20050154007-A1 | New compounds | SLC10A2, GIPR, FABP6 | KDM4E 4725/4885MEN1 3476/4885RECQL 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.